Drug Safety in COPD Revisited-Reference-Cited by-同舟云学术

Drug Safety in COPD Revisited

Published:2012-08 Issue:2 Volume:142 Page:271-274
ISSN:0012-3692
Container-title:Chest
language:en
Short-container-title:Chest

Author:

Rabe Klaus F.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Reference27 articles.

1. Optimum bronchodilator combinations in chronic obstructive pulmonary disease: what is the current evidence?;Miles;Drugs,2012

2. New drugs for exacerbations of chronic obstructive pulmonary disease;Hansel;Lancet,2009

3. Outcomes and costs associated with initial maintenance therapy with fluticasone propionate-salmeterol xinafoate 250 microg/50 microg combination versus tiotropium in commercially insured patients with COPD;Dalal;Manag Care,2011

4. Cost effectiveness of tiotropium for chronic obstructive pulmonary disease: a systematic review of the evidence;Mauskopf;J Media Econ,2010

5. Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy;Zaniolo;Eur J Health Econ,2012

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bronchodilator Safety in Chronic Obstructive Pulmonary Disease;JAMA Internal Medicine;2014-04-01

2. Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: A meta-analysis;Pulmonary Pharmacology & Therapeutics;2014-02

3. Medikamentöse Therapie von Herz- und Lungenerkrankungen;Herz;2014-01-24

4. Hospitalization Due to COPD Exacerbation;Chest;2012-12